The multiple faces of glucagon-like peptide-1 - Obesity, appetite, and stress: What is next? A review

Digestive Diseases and Sciences

Volumn 52, Issue 3, 2007, Pages 643-649

  Frezza, Eldo E ^a   Wachtel, Mitchell S ^b   Chiriva Internati, Maurizio ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

Appetite; Bariatric surgery; Ghrelin; GLP 1; Incretins; Obesity; Oxyntomodulin; Satiety; Stress; Type 2 diabetes

Indexed keywords

ALBUGON; CJC 1131; DIPEPTIDYL PEPTIDASE IV; EXCRETIN; EXENDIN 4; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; OXYNTOMODULIN; PEPTIDE YY; PROTEIN; UNCLASSIFIED DRUG;

APPETITE; CONTINUOUS INFUSION; DECREASED APPETITE; DRUG DEGRADATION; DRUG INDICATION; DRUG POTENCY; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; STOMACH BYPASS; STRESS;

ANIMALS; APPETITE; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OBESITY; OXIDATIVE STRESS; OXYNTOMODULIN; PEPTIDE HORMONES; PEPTIDE YY;

EID: 33847229483     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9096-2     Document Type: Review

References (91)

1. Perry T, Lahiri DK, Chen D, et al. (2002) A novel neurotrophic property of glucagon-like peptide-1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958-966
2. Fehmann HC, Göke R, Göke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390-410
3. Naslund E, Hellstrom PM (1998). Glucagon-like peptide-1 in the pathogenesis of obesity. Drug News Perspect 11:92-97
4. Gutzwiller JP, Tschopp S, Bock A, et al. (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrin Metab 89:3055-3061
5. Eissele R, Goke R, Willemer S, et al. (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283-291
6. Jin SL, Han VK, Simmons JG, et al. (1988) Distribution of glucagon-like peptide-1 (GLP-1), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519-532
7. Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261-280
8. Rouille Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270:26488-26496
9. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992) Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276
10. Holst JJ (1997) Enteroglucagon. Annu Rev Physiol 59:257-271
11. Kreymann B, Williams G, Ghatei MA, et al. (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
12. Yoshimoto S, Hirota M, Ohboshi C, et al. (1989) Identification of glucagon-like peptide-1 (7-36) amide in rat brain. Ann Clin Biochem 26:169-171
13. Ørskov C, Rabenhøj L, Wettergren A, et al. (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539
14. Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001-8008
15. Kreymann B, Ghatei MA, Burnet P, et al. (1989) Characterization of glucagon-like peptide 1-(7-36)amide in the hypothalamus. Brain Res 502:325-331
16. Ritzel R, Ørskov C, Holst JJ, et al. (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties ofGLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response- relationships. Diabetologia 38:720-725
17. Creutzfeldt WO, Kleine N, Willms B, et al. (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I [7-36 amide] in type I diabetic patients. Diabetes Care 19:580-586
18. N̈aslund E, Bogefors J, Skogar S, et al. (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277:R910-916
19. Flint A, Raben A, Ersboll AK, et al. (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substratemetabolism in obesity. Int J Obes Relat Metab Disord 25:781-792
20. Meier S, Hucking K, Titzel R, et al. (2003) Absence of a memory effect for the insulinotropic action of glucagon-like peptide-1 (GLP-1) in healthy volunteers. Horm Met Res 35:551-556
21. Silvestre RA, Rodriguez-Gallardo J, Egido EM, et al. (2003) Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 469:195-200
22. Ling Z, Wu D, Zambre Y, et al. (2001) Glucagon-like peptide-1 receptor signalling influences topography of islet cells in mice. Virchows Archiv 438:382-387
23. Nagai K, Tsuchiya K, Ezaki T, et al. (2004) Effect of GLP-1 (glucagon-like peptide-1:7-36 amide) on porcine pancreatic endocrine cell proliferation and insulin secretion. Pancreas 28:138-145
24. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA (2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269-279
25. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
26. Gutzwiller JP, Goke B, Drewe J, et al. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81-86
27. Gutzwiller JP, Drewe J, Goke B, et al. (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-1544
28. Toft-Nielsen MB, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143
29. Verdich C, Toubro S, Buemann B, et al. (2001) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206-1214
30. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781-792
31. Kalra SP, Dube MG, Pu MG, et al. (1999) Interacting appetitere-gulating pathways in the hypothalamic regulation of body weight. Endocrine Rev 20:68-100
32. SchwartzMW, Baskin DG, Kaiyala KJ, et al. (1999) Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr 69:584-596
33. Meeran K, O'Shea D, Edwards CM, et al. (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244-250
34. Larsen PJ, Tang-Christensen M, Jessop DS (1997) Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445-4455
35. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695
36. Shughrue PJ, Lane MV, Merchenthaler I (1996) Glucagon-like peptide-1 receptor (GLP-1-R) mRNA in the rat hypothalamus. Endocrinology 137:5159-5162
37. Dakin CL, Small CJ, Park AJ, et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol 283:E1173-1177
38. Dakin CL, Gunn I, Small CJ, et al. (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244-4250
39. Dakin CL, Small CJ, Park AJ, et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol 283:E1173-1177
40. Tang-Christensen M, Vrang N, Larsen PJ (2001) Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25[Suppl 5]:S42-47
41. Fehmann HC, Jiang J, Schweinfurth J, et al. (1994) Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I (7-36) -amide, oxyntomodulin, exendin-4, and exendin (9-39). Peptides 15:453-456
42. Dakin CL, Small CJ, Batterham RL, et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695
43. Yamamoto H, Kishi T, Lee CE, et al. (2003) Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939-2946
44. Cohen MA, Ellis SM, Le Roux CW, et al. (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696-701
45. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070-1077
46. Sarkar S, Fekete C, Legradi G, et al. (2003) Glucagon-like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 985:163-168
47. Alvarez E, Roncero I, Chowen JA, et al. (1996) Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 66:920-997
48. Møller C, Sommer W, Thorsell A, et al. (2002) Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog Neuropsychopharmacol Biol Psychiatry 26:119-122
49. Kinzig KP, D'Alessio DA, Herman JP, et al. (2003) CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 23:6163-6170
50. Malendowicz LK, Nussdorfer GG, Nowak KW, et al. (2003) Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: investigations into the mechanism(s) underlying Ex4 effect. Int J Mol Med 12:237-241
51. Rinaman L (1999) Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 277:R582-590
52. MacLusky NJ, Cook S, Scrocchi L, et al. (2000) Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 141:752-762
53. Andreis PG, Malendowicz LK, Neri G, et al. (1999) Effects of glucagon and glucagon-like peptide-1 on glucocorticoid secretion of dispersed rat adrenocortical cells. Life Sci 64:2187-2197
54. Peters CT, Choi YH, Brubaker PL, et al. (2001) A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutient selection by rats. J Nutr 131:2164-2170
55. Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H (1999) Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutrition 129:46-50
56. Vilsboll T, Krarup T, Sonne J, et al. (2003) Incretin secretion in relation tomeal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706-2713
57. Vilsboll T, Agerso H, Krarup T, et al. (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224
58. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, et al. (2003) Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 27:1359-1364
59. Feinle C, Chapman IM, Wishart J, et al. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491-1495
60. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38:916
61. Tomasik PJ, Sztefko K, Malek A (2002) GLP-1 as a satiety factor in children with eating disorders. Horm Metab Res 34:77-80
62. Lugari R, Dei Cas A, Ugolotti D, et al. (2004) Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36:111-115
63. Fukase N, Igarashi M, Takahashi H, et al. (1993) Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 10:44-49
64. Feinle C, Chapman IM, Wishart J, et al. (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491-1495
65. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, et al. (2003) Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 27:1359-1364
66. Lugari R, Dei Cas A, Ugolotti D, et al. (2004) Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36:111-115
67. Navarro M, Rodriguez de Fonseca F, Alvarez E, et al. (1996) Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transported GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67:1982-1991
68. Meier JJ, Gallwitz B, Schmidt WE, et al. (2002) Glucagon-like peptide-1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269-279
69. Larsen PJ, Vrang N, Tang-Christensen M (2003) Central preproglucagon derived peptides: opportunities for treatment obesity. Curr Pharm Des 9:1373-1382.
70. Young AA, Gedulin BR, Bhavsar S, et al. (1999) Glucose-lowering and insulin-sensitizing actions of Exendin-4: Studies in obese diabetic (ob(ob, db(db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034
71. Szayna M, Doyle ME, Betkey JA, et al. (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941
72. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530-2539
73. Naslund E (2004) Prandial subcutaneous injections of GLP-1 cause weight loss in obese human subjects. Br J Nutr 91:439-446
74. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, et al. (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151-159
75. Batterham RL, Cowley MA, Small CJ, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
76. Halatchev IG, Ellacott KL, Fan W, et al. (2004) Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145:2585-2590
77. Kojima M, Hosoda H, Date Y, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660
78. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al. (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48:23-29
79. Katayama M, Nogami H, Nishiyama J, Kawase T, Kawamura K (2000) Developmentally and regionally regulated expression of growth hormone secretagogue receptor mRNA in rat brain and pituitary gland. Neuroendocrinology 72:333-340
80. Shintani M, Ogawa Y, Ebihara K, et al. (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y(Y1 receptor pathway. 50:227-232
81. Clark JT, Kalra PS, Kalra SP (1985) Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 117:2435-2442
82. Cummings DE, Purnell JQ, Frayo RS, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714-1719
83. Wren AM, Seal LJ, Cohen MA, et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992
84. Nakazato M, Murakami N, Date Y, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194-198
85. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, et al. (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325-4328
86. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540-2547
87. Laferrere B, Abraham C, Russell CD, et al. (2005) Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 90:611-614
88. Frezza EE (2004) Are we closer in finding the treatment for type ii diabetes mellitus in morbid obesity - are the incretins the key to success? Obesity Surgery 14:999-1005
89. Cummings DE, Shannon MH (2003) Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 88:2999-3002
90. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, et al. (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236-242
91. Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, et al. (1997) Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21:387-392